Marc Lacroix

	WikiDoc Resources for Marc Lacroix
Articles
Most recent articles on Marc Lacroix Most cited articles on Marc Lacroix Review articles on Marc Lacroix Articles on Marc Lacroix in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Marc Lacroix Images of Marc Lacroix Photos of Marc Lacroix Podcasts & MP3s on Marc Lacroix Videos on Marc Lacroix
Evidence Based Medicine
Cochrane Collaboration on Marc Lacroix Bandolier on Marc Lacroix TRIP on Marc Lacroix
Clinical Trials
Ongoing Trials on Marc Lacroix at Clinical Trials.gov Trial results on Marc Lacroix Clinical Trials on Marc Lacroix at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Marc Lacroix NICE Guidance on Marc Lacroix NHS PRODIGY Guidance FDA on Marc Lacroix CDC on Marc Lacroix
Books
Books on Marc Lacroix
News
Marc Lacroix in the news Be alerted to news on Marc Lacroix News trends on Marc Lacroix
Commentary
Blogs on Marc Lacroix
Definitions
Definitions of Marc Lacroix
Patient Resources / Community
Patient resources on Marc Lacroix Discussion groups on Marc Lacroix Patient Handouts on Marc Lacroix Directions to Hospitals Treating Marc Lacroix Risk calculators and risk factors for Marc Lacroix
Healthcare Provider Resources
Symptoms of Marc Lacroix Causes & Risk Factors for Marc Lacroix Diagnostic studies for Marc Lacroix Treatment of Marc Lacroix
Continuing Medical Education (CME)
CME Programs on Marc Lacroix
International
Marc Lacroix en Espanol Marc Lacroix en Francais
Business
Marc Lacroix in the Marketplace Patents on Marc Lacroix
Experimental / Informatics
List of terms related to Marc Lacroix

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Marc Lacroix is a biochemist (educated at University of Liège) and a researcher (born 1963 in Verviers, Wallonia, Belgium) who specializes in breast cancer biology, metastasis and therapy ^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]^[15]^[16]^[17]^[18]^[19]^[20]^[21]^[22]^[23]^[24]^[25]^[26]^[27] .
He works at Institut Jules Bordet (Brussels, Belgium).

Earlier work

Recent work

The amount of data on breast cancer available for the scientific and medical community is growing rapidly. According to PubMed, a search engine offering access to the MEDLINE database of citations and abstracts of biomedical research articles, 7918 papers containing the expression «breast cancer» were published in 2006. Their number was 3592 in 1996, 1455 in 1986 and only 626 in 1976. In general, the older information is overlayed by more recent data and forgotten to some extent. In 2004, Lacroix and colleagues collected and assembled data from hundreds of articles related to the biology, pathology and genetics of in situ, invasive and metastatic breast cancers. These papers were covering a time period of about 25 years. Lacroix et al. concluded that despite undergoing increasing genetic alteration, most individual breast cancers rather surprisingly maintain their phenotype when they evolve from in situ to the metastatic state ^[28]. This conclusion was in opposition to a progression model widely accepted at that time, which was suggesting that carcinoma in situ could evolve into invasive carcinoma and subsequently produce metastases through an accumulation of molecular abnormalities possibly allowing extensive phenotype changes and subsequent gain of aggressiveness.

Bibliography: articles in scientific and medical journals

↑ Body, JJ (1994). "lymphocyte calcitonin receptors". Calcified Tissue International. 55: 109–113. PMID 7953975. Unknown parameter |coauthors= ignored (help)
↑ Jin, L (1995). "Antiestrogenic activity of 2 11-beta-estradiol derivatives on MCF-7 breast cancer cells". Steroids. 60: 512–518. PMID 8539793. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (1995). "Keratinocytes modulate the biosynthetic phenotype of dermal fibroblasts at a pretranslational level in human skin equivalent". Archives of Dermatological Research. 287: 659–664. PMID 8534130. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (1996). "Effects of secretory products of breast cancer cells on osteoblast-like cells". Breast Cancer Research and Treatment. 38: 209–216. PMID 8861839. Unknown parameter |coauthors= ignored (help)
↑ Siwek, B (1997). "Secretory products of breast cancer cells specifically affect human osteoblastic cells: Partial characterization of active factors". Journal of Bone and Mineral Research. 12: 552–560. PMID 9101366. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (1997). "c-fos". Calcified Tissue International. 60: 513–519. PMID 9164825. Unknown parameter |coauthors= ignored (help)
↑ Borras, M (1997). "Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers". Cancer Letters. 120: 23–30. PMID 9570382. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (1998). "Breast cancer cell response to calcitonin: Modulation by growth-regulating agents". European Journal of Pharmacology. 344: 279–286. PMID 9600664. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (1998). "interleukin-11". Cancer Letters. 127: 29–35. PMID 9619855. Unknown parameter |coauthors= ignored (help)
↑ Siwek, B (1998). "Establishment and characterization of three new breast-cancer cell lines". International Journal of Cancer. 76: 677–683. PMID 9610725. Unknown parameter |coauthors= ignored (help)
↑ Sotiriou, C (1999). "The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11". Anticancer Research. 19: 2997–3006. PMID 10652584. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2000). "Protein production by osteoblasts: modulation by breast cancer cell-derived factors". Breast Cancer Research and Treatment. 61: 59–67. PMID 10930090. Unknown parameter |coauthors= ignored (help)
↑ Maaroufi, Y (2000). "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis". Breast Cancer Research. 2: 444–454. PMID 11056692. Unknown parameter |coauthors= ignored (help)
↑ Sotiriou, C (2001). "Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases". Cancer Letters. 169: 87–95. PMID 11410329. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2001). "Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison". Breast Cancer Research and Treatment. 67: 263–271. PMID 11561772. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2002). "A low-density DNA microarray for analysis of markers in breast cancer". International Journal of Biological Markers. 17: 5–23. PMID 11936587. Unknown parameter |coauthors= ignored (help)
↑ Rivas, A (2002). "Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells". Journal of Steroid Biochemistry and Molecular Biology. 82: 45–53. PMID 12429138. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Cancer Research and Treatment. 83: 249–289. PMID 14758095. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2004). "About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer". Molecular and Cellular Endocrinology. 219: 1–7. PMID 15149721. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2004). "Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes". Oncology Reports. 12: 701–707. PMID 15375488. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2005). "The "portait" of hereditary breast cancer". Breast Cancer Research and Treatment. 89: 297–304. PMID 15754129. Unknown parameter |coauthors= ignored (help)
↑ De Longueville, F (2005). "Molecular characterization of breast cancer cell lines by a low-density microarray". International Journal of Oncology. 27: 881–892. PMID 16142302. Unknown parameter |coauthors= ignored (help)
↑ Toillon, RA (2005). "Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells". Breast Cancer Research and Treatment. 93: 207–215. PMID 16136271. Unknown parameter |coauthors= ignored (help)
↑ Leclercq, G (2006). "Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells". Current Cancer Drug Targets. 6: 39–64. PMID 16475975. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2006). "P53 and breast cancer, an update". Endocrine-Related Cancer. 13: 293–325. PMID 16728565. Unknown parameter |coauthors= ignored (help)
↑ Lacroix., M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer. 13: 1033–1067. PMID 17158753.
↑ Toillon, RA (2007). "Estrogens decrease gamma-rays induced senescence and maintain cell cycle progression in breast cancer cells independently of p53". International Journal of Radiation Oncology, Biology, Physics. 67: 1187–1200. PMID 17336220. Unknown parameter |coauthors= ignored (help)
↑ Lacroix, M (2004). "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics". Endocrine-Related Cancer. 11: 497–522. PMID 15369451. Unknown parameter |coauthors= ignored (help)

Bibliography: invited chapters in thematic books

Leclercq G, Lacroix M, Seo HS, Larsimont D. "Mechanisms regulating oestrogen receptor alpha expression in breast cancer.", in "Molecular Mechanisms of Action of Steroid Hormone Receptors" 65-75 (2002). Editors: Marija Krstic-Demonacos & Constantinos Demonacos, Research Signpost Publishers, Trivandrum, India, ISBN 81-7736-129-5, http://www.ressign.com/

Lacroix M, Leclercq G. "An updated view on cell lines as in vitro models for breast tumors.", in "Focus on Breast Cancer Research" 131-182 (2004). Editor: Andrew P. Yao, Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, ISBN 1-59033-961-4, https://www.novapublishers.com/catalog/product_info.php?products_id=593

Sotiriou C, Desmedt C, Durbecq V, Dal Lago L, Lacroix M, Cardoso F, Piccart M. "Genomic and molecular classification of breast cancer.", in "Molecular Oncology of Breast Cancer" 81-95 (2004). Editors: Jeffrey S. Ross and Gabriel N. Hortobagy, Jones and Bartlett Publishers, 40 Tall Pine Drive, Sudbury, MA 01776 USA, ISBN 0-76374-810-2, http://www.jbpub.com/catalog/0763748102/table_of_contents.htm

Lacroix M, Leclercq G. "Hereditary breast cancer: an update on genotype and phenotype.",in "New Breast Cancer Research" 27-51 (2006). Editor: Andrew P. Yao, Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, ISBN 1-59454-932-X, https://www.novapublishers.com/catalog/product_info.php?products_id=4134

(in press) Lacroix M. "An update on tumor suppressor genes in breast cancer.", in "Tumor Suppressor Genes" (2007). Editor: Katherine R. Polinsky, Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, ISBN 1-60021-693-5, http://www.novapublishers.com/catalog/product_info.php?products_id=5679

References

Over the years, Marc Lacroix has been refereeing for several international scientific and clinical journals:

Resources

Free access to "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics"
Free access to "P53 and breast cancer, an update"
Free access to "Significance, detection and markers of disseminated breast cancer cells"
Université libre de Bruxelles – Marc Lacroix

Template:WikiDoc Sources

[Body1-1] Body, JJ (1994). "lymphocyte calcitonin receptors". Calcified Tissue International. 55: 109–113. PMID 7953975. Unknown parameter |coauthors= ignored (help)

[Jin1-2] Jin, L (1995). "Antiestrogenic activity of 2 11-beta-estradiol derivatives on MCF-7 breast cancer cells". Steroids. 60: 512–518. PMID 8539793. Unknown parameter |coauthors= ignored (help)

[Lacroix1-3] Lacroix, M (1995). "Keratinocytes modulate the biosynthetic phenotype of dermal fibroblasts at a pretranslational level in human skin equivalent". Archives of Dermatological Research. 287: 659–664. PMID 8534130. Unknown parameter |coauthors= ignored (help)

[Lacroix2-4] Lacroix, M (1996). "Effects of secretory products of breast cancer cells on osteoblast-like cells". Breast Cancer Research and Treatment. 38: 209–216. PMID 8861839. Unknown parameter |coauthors= ignored (help)

[Siwek1-5] Siwek, B (1997). "Secretory products of breast cancer cells specifically affect human osteoblastic cells: Partial characterization of active factors". Journal of Bone and Mineral Research. 12: 552–560. PMID 9101366. Unknown parameter |coauthors= ignored (help)

[Lacroix3-6] Lacroix, M (1997). "c-fos". Calcified Tissue International. 60: 513–519. PMID 9164825. Unknown parameter |coauthors= ignored (help)

[Borras1-7] Borras, M (1997). "Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers". Cancer Letters. 120: 23–30. PMID 9570382. Unknown parameter |coauthors= ignored (help)

[Lacroix4-8] Lacroix, M (1998). "Breast cancer cell response to calcitonin: Modulation by growth-regulating agents". European Journal of Pharmacology. 344: 279–286. PMID 9600664. Unknown parameter |coauthors= ignored (help)

[Lacroix5-9] Lacroix, M (1998). "interleukin-11". Cancer Letters. 127: 29–35. PMID 9619855. Unknown parameter |coauthors= ignored (help)

[Siwek2-10] Siwek, B (1998). "Establishment and characterization of three new breast-cancer cell lines". International Journal of Cancer. 76: 677–683. PMID 9610725. Unknown parameter |coauthors= ignored (help)

[Sotiriou1-11] Sotiriou, C (1999). "The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11". Anticancer Research. 19: 2997–3006. PMID 10652584. Unknown parameter |coauthors= ignored (help)

[Lacroix6-12] Lacroix, M (2000). "Protein production by osteoblasts: modulation by breast cancer cell-derived factors". Breast Cancer Research and Treatment. 61: 59–67. PMID 10930090. Unknown parameter |coauthors= ignored (help)

[Maaroufi1-13] Maaroufi, Y (2000). "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis". Breast Cancer Research. 2: 444–454. PMID 11056692. Unknown parameter |coauthors= ignored (help)

[Sotiriou2-14] Sotiriou, C (2001). "Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases". Cancer Letters. 169: 87–95. PMID 11410329. Unknown parameter |coauthors= ignored (help)

[Lacroix7-15] Lacroix, M (2001). "Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison". Breast Cancer Research and Treatment. 67: 263–271. PMID 11561772. Unknown parameter |coauthors= ignored (help)

[Lacroix8-16] Lacroix, M (2002). "A low-density DNA microarray for analysis of markers in breast cancer". International Journal of Biological Markers. 17: 5–23. PMID 11936587. Unknown parameter |coauthors= ignored (help)

[Rivas2-17] Rivas, A (2002). "Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells". Journal of Steroid Biochemistry and Molecular Biology. 82: 45–53. PMID 12429138. Unknown parameter |coauthors= ignored (help)

[Lacroix9-18] Lacroix, M (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Cancer Research and Treatment. 83: 249–289. PMID 14758095. Unknown parameter |coauthors= ignored (help)

[Lacroix10-19] Lacroix, M (2004). "About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer". Molecular and Cellular Endocrinology. 219: 1–7. PMID 15149721. Unknown parameter |coauthors= ignored (help)

[Lacroix12-20] Lacroix, M (2004). "Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes". Oncology Reports. 12: 701–707. PMID 15375488. Unknown parameter |coauthors= ignored (help)

[Lacroix13-21] Lacroix, M (2005). "The "portait" of hereditary breast cancer". Breast Cancer Research and Treatment. 89: 297–304. PMID 15754129. Unknown parameter |coauthors= ignored (help)

[De_Longueville1-22] De Longueville, F (2005). "Molecular characterization of breast cancer cell lines by a low-density microarray". International Journal of Oncology. 27: 881–892. PMID 16142302. Unknown parameter |coauthors= ignored (help)

[Toillon1-23] Toillon, RA (2005). "Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells". Breast Cancer Research and Treatment. 93: 207–215. PMID 16136271. Unknown parameter |coauthors= ignored (help)

[Leclercq1-24] Leclercq, G (2006). "Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells". Current Cancer Drug Targets. 6: 39–64. PMID 16475975. Unknown parameter |coauthors= ignored (help)

[Lacroix14-25] Lacroix, M (2006). "P53 and breast cancer, an update". Endocrine-Related Cancer. 13: 293–325. PMID 16728565. Unknown parameter |coauthors= ignored (help)

[Lacroix15-26] Lacroix., M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer. 13: 1033–1067. PMID 17158753.

[Toillon2-27] Toillon, RA (2007). "Estrogens decrease gamma-rays induced senescence and maintain cell cycle progression in breast cancer cells independently of p53". International Journal of Radiation Oncology, Biology, Physics. 67: 1187–1200. PMID 17336220. Unknown parameter |coauthors= ignored (help)

[Lacroix11-28] Lacroix, M (2004). "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics". Endocrine-Related Cancer. 11: 497–522. PMID 15369451. Unknown parameter |coauthors= ignored (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]